Treatment of murine fusariosis with SCH 56592

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 589-591

  Lozano Chiu, M ^a,d   Arikan, S ^a   Paetznick, V L ^a   Anaissie, E J ^b   Loebenberg, D ^c   Rex, J H ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BODY BURDEN; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; FUSARIUM SOLANI; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

EID: 0032979512     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.589     Document Type: Article

References (26)

1. Anaissie, E., H. Kantarjian, J. Ro, R. Hopfer, K. Rolston, V. Fainstein, and G. Bodey. 1988. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 67:77-83.
2. Anaissie, E. J., R. Hachem, C. Legrand, P. Legenne, P. Nelson, and G. P. Bodey. 1992. Lack of activity of amphotericin B in systemic murine fusarial infection. J. Infect. Dis. 165:1155-1157.
3. Anaissie, E. J., and M. G. Rinaldi. 1990. Fusarium and the immunocompromised host: liaisons dangeureuses. N. Y. State J. Med 90:586-587. (Comment.)
4. Attapattu, M. C., and C. Anandakrishnan. 1986. Extensive subcutaneous hyphomycosis caused by Fusarium oxysporum. J. Med. Vet. Mycol. 24:105-111.
5. Collins, M. S., and M. G. Rinaldi. 1977. Cutaneous infection in man caused by Fusarium moniliforme. Sabouraudia 12:151-160.
6. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39: 314-319.
7. Fisher, N. L., L. W. Burgess, T. A. Tourssoun, and P. E. Nelson. 1982. Carnation leaves as substrate and for preserving cultures of Fusarium species. Phytopathology 72:151-153.
8. Guarro, J., and J. Gene. 1995. Opportunistic fusarial infections in humans. Eur. J. Clin. Microbiol. Infect. Dis. 14:741-754.
9. Law, D., C. B. Moore, and D. W. Denning. 1997. Activity of SCH 56592 compared with those of fluconazole and intraconazole against Candida spp. Antimicrob. Agents Chemother. 41:2310-2311.
10. Lozano, M., J. M. Ribera, J. Puig, A. Rives, J. Sierra, R. Grañena, and C. Rozman. 1990. Bronconeumonia por Fusarium solani en un paciente afectado de leucemia aguda mieloblastica. Enferm. Infece. Microbol. Clin. 8: 78-79.
11. 10a. Lozano-Chiu, M., S. Arikan, V. Paetznick, E. J. Anaissle, D. Loebenberg, and J. H. Rex. 1998. Successful treatment of murine fusariosis with Schering (SCH) 56592, abstr. F-101, p. 270. In Abstracts of the 98th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
12. Lutz, J. E., K. V. Clemons, B. H. Aristizabal, and D. A. Stevens. 1997. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. 41:1558-1561.
13. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A, National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Nelson, P. E., M. C. Dignani, and E. J. Anaissie. 1994. Taxonomy, biology, and clinical aspects of Fusarium species. Clin. Microbiol. Rev. 7:474-504.
15. Neumeister, B., P. Bartmann, G. Gaedicke, and R. Marre. 1992. A fatal infection due to Fusarium oxysporum in a child with Wilms's tumour. Case report and review of the literature. Mycoses 35:115-119.
16. Oakley, K. L., G. Morrisey, and D. W. Denning. 1997. Efficacy of SCH 56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus, Antimicrob. Agents Chemother. 41:1504-1507.
17. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole. Sch 56592, compared with those of four antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
18. Pujol, I., J. Guarro, J. Gene, and J. Sala. 1997. In vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J. Antimicrob. Chemother. 39:163-167.
19. Rabodonirina, M., M. A. Piens, M. F. Monier, E. Gueho, D. Fiere, and M. Mojon. 1994. Fusarium infections in immunocompromised patients: case reports and literature review. Eur. J. Clin. Microbiol. Infect. Dis. 13:152-161.
20. Reuben, A., E. Anaissie, P. E. Nelson, R. Hashem, C. Legrand, D. H. Ho, and G. P. Bodey. 1989. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob. Agents Chemother. 33:1647-1649.
21. Sanche, S. E., D. A. Sutton, K. Magnon, P. Cox, S. Revankar, and M. G. Rinaldi. 1998. Psuedoepidemic of Fusarium oxysporum from bronchoscopy specimens, abstr. F-102, p. 270. In Abstracts of the 98th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
22. 20a. Schering Plough Research Institute. Data on file.
23. Sekhon, A. S., A. A. Padhye, A. K. Garg, H. Ahmad, and N. Moledina. 1994. In vitro sensitivity of medically significant Fusarium species to various antimycotics. Chemotherapy 40:239-244.
24. Srdic, N., S. Radulovic, Z. Nonkovic, S. Velimirovic, L. Cvetkovic, and I. Viro. 1993. Two cases of exogenous endophthalmitis due to Fusarium moniliforme and Pseudomonas species as associated actiological agents. Mycoses 36:441-444.
25. Sugar, A. M., and X.-P. Liu. 1996. In vitro and in vivo activities of SCH 56542 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. 40:1314-1316.
26. Vartivarian, S. E., E. J. Anaissie, and G. P. Bodey. 1993. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis 17:S487-S491.